Leukemia · 2020 · 36 citations · 38 references
MedicineOncologyPharmacologyMolecular OncologyOncogenesTumor MicroenvironmentReceptor Tyrosine Kinase OncogenesSignal Transduction In CancerTherapeutic ResistanceTyrosine Kinase InhibitorsBcr-abl InhibitorsBcr-abl1 Fusion GeneChronic Myeloid Leukemia TherapyFibronectin FunctionKinase InhibitorsNiche Cell InteractionsResistance To Tyrosine Kinase InhibitorsTherapeutic Resistance Mechanisms
Abstract Therapy resistance in leukemia may be due to cancer cell-intrinsic and/or -extrinsic mechanisms. Mutations within BCR-ABL1 , the oncogene giving rise to chronic myeloid leukemia (CML), lead to resistance to tyrosine kinase inhibitors (TKI), and some are associated with clinically more aggressive disease and worse outcome. Using the retroviral transduction/transplantation model of CML and human cell lines we faithfully recapitulate accelerated disease course in TKI resistance. We show in various models, that murine and human imatinib-resistant leukemia cells positive for the oncogene BCR-ABL1 T315I differ from BCR-ABL1 native ( BCR-ABL1 ) cells with regards to niche location and specific niche interactions. We implicate a pathway via integrin β3, integrin-linked kinase (ILK) and its role in deposition of the extracellular matrix (ECM) protein fibronectin as causative of these differences. We demonstrate a trend towards a reduced BCR-ABL1 T315I+ tumor burden and significantly prolonged survival of mice with BCR-ABL1 T315I+ CML treated with fibronectin or an ILK inhibitor in xenogeneic and syngeneic murine transplantation models, respectively. These data suggest that interactions with ECM proteins via the integrin β3/ILK-mediated signaling pathway in BCR-ABL1 T315I+ cells differentially and specifically influence leukemia progression. Niche targeting via modulation of the ECM may be a feasible therapeutic approach to consider in this setting.
38
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Andrei V. Krivtsov, David Twomey, Zhaohui Feng et al. · Nature · 2006 · 1.5K citations
Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche
Cristina Lo Celso, Heather E. Fleming, Juwell W. Wu et al. · Nature · 2008 · 912 citations · Full text
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 596 citations